Stevanato Group (NYSE:STVN – Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of EUR0.51-0.55 for the period, compared to the consensus estimate of $0.62. The company issued revenue guidance of EUR1.125-1.155 billion, compared to the consensus revenue estimate of $1.19 billion.
Wall Street Analyst Weigh In
A number of research analysts have commented on STVN shares. Morgan Stanley reiterated an equal weight rating and issued a $30.00 price objective on shares of Stevanato Group in a research report on Monday, April 22nd. BNP Paribas initiated coverage on Stevanato Group in a research report on Monday, April 22nd. They issued an outperform rating for the company. Finally, Stephens restated an overweight rating and set a $38.00 target price on shares of Stevanato Group in a research report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of €34.29 ($36.87).
Check Out Our Latest Research Report on Stevanato Group
Stevanato Group Trading Down 11.6 %
Stevanato Group (NYSE:STVN – Get Free Report) last issued its quarterly earnings data on Thursday, March 7th. The company reported €0.18 ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.19 ($0.20) by (€0.01) (($0.01)). The firm had revenue of €320.60 million for the quarter, compared to analyst estimates of €326.85 million. Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 EPS. Equities analysts expect that Stevanato Group will post 0.67 EPS for the current year.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Read More
- Five stocks we like better than Stevanato Group
- Quiet Period Expirations Explained
- How to Bet on a Large Stock Price Move with an Options Strangle
- Market Cap Calculator: How to Calculate Market Cap
- Shopify Stock Took a Breather, Markets Stay Bullish On its Future
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- No New Highs for Cloudflare in 2024
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.